Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CoV2 preS dTM [B.1.351]
- Development stage
- Phase 2
- Lead developer
- Sanofi Pasteur
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
CoV2 preS dTM [B.1.351] is a soluble trimeric SARS-CoV-2 recombinant spike (S) protein derived from the B.1.351 (Beta) variant. It is stabilized in its prefusion conformation and has its transmembrane and intracellular domains deleted. This antigen is produced using a baculovirus expression system in an insect cell line. It functions as an active ingredient in adjuvanted vaccines, typically combined with the AS03 adjuvant system, to induce an immune response against SARS-CoV-2, specifically targeting the B.1.351 variant. The development of this antigen and its associated vaccines has been a collaborative effort between Sanofi and GSK.
- Other names
- SARS-CoV-2 spike protein (B.1.351 strain)recombinant CoV-2 Spike Protein (B.1.351) antigen
02
Targets
SARS-CoV-2 spike
Beyond the preview
Go deeper on CoV2 preS dTM [B.1.351].
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CoV2 preS dTM [B.1.351].